We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.
+ 34-608-087-655
Title Image

Right Sidebar

Home  /  Blog  /  Right Sidebar

Novo Ventures, part of Novo Holdings, today announced that it has led the $55 million (£44 million) Series B financing in NodThera, a UK and US based clinical stage biotechnology company developing a new class of medicines to treat diseases driven by chronic inflammation. Nanna Lüneborg, Partner at Novo Ventures, will join the NodThera board and investors database. NodThera is focusing on an exciting new class of anti-inflammatory targets, the NLRP3 inflammasome. Therapeutics that disrupt the NLRP3 inflammasome to inhibit damaging inflammatory processes have the potential to help patients with many chronic diseases. In preclinical studies, NT-0167 demonstrated potent and selective inhibition of the

Solvias Completes Agreement with Strategic Healthcare Investors to Advance Expansion Global Pharmaceutical Laboratory Services Company Appoints Two Seasoned Industry Executives to Board of Directors - Solvias Completes Agreement with Strategic Healthcare Investors to Advance Expansion . Solvias, a world leader in contract research, development and manufacturing, today announced that it has completed an agreement with strategic health care investors, Water Street Healthcare Partners and JLL Partners, to fully acquire and invest in growing Solvias.  The agreement is the next step in Solvias' expansion focused on building the company into a global leader of high-quality pharmaceutical laboratory services and having onbaord a very powerful and

BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in Alzheimer's disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007. In

Elsevier, a global information analytics business specializing in science and health, and part of RELX, has acquired 3D4Medical, the global anatomy education company headquartered in Dublin, Ireland. 3D4Medical created Complete Anatomy, the world's most advanced 3D anatomy platform, revolutionizing how students, educators, health professionals and patients understand and interact with anatomy. With outstanding technology and design that pushes the boundaries of how people learn using advanced 3D visualization tools, Complete Anatomy has garnered more than a million registered users at more than 300 of the world's top universities.   "When we started 3D4Medical, we wanted to disrupt the way anatomy was taught and

TauRx has reportedunexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease. These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy. "Since we already have a substantial database supporting the safety and tolerability of hydromethylthionine in clinical trials of patients with mild-to-moderate Alzheimer's disease, the additional results of this analysis have given us the confidence

Sekisui Diagnostics' Enzyme business unveiled its new Bioprocess Innovation Centre at its site near Maidstone, Kent, UK. The new R&D facility, costing $1.9 million, is part of a long-term investment strategy to grow its share of the Microbial Biopharma CDMO market, with future investment expected to focus on expanding its cGMP manufacturing capabilities, starting with additional ISO 8 clean room capacity coming online by the end of 2019. "This investment represents our commitment to serve our customers with innovative process development solutions," said Will Stockburn, Sekisui Diagnostics (UK) Ltd.'s General Manager. "Over many years we have built a technical competency in

Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of its Biologics License Application (“BLA”) for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma under the FDA’s Rolling Review process. “We are excited to announce the initiation of the rolling BLA for naxitamab, a major milestone for Y-mAbs. Dr. Nai-Kong Cheung and his research team at Memorial Sloan Kettering Cancer Center (“MSK”) started looking at immunotherapy more than three

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for spinal muscular atrophy (SMA). Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body. The FDA is expected to make a decision on approval by May 24, 2020. “The FIREFISH and SUNFISH trials were designed to represent the real world spectrum of people living with SMA and include many people

Celularity, a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM). Results from pre-clinical studies demonstrated in vivo anti-GBM activity of CYNK-001. “The positive results from these pre-clinical studies highlight the versatility and activity of our investigational, off-the-shelf, placental-derived NK cell therapy program,” said Robert Hariri, M.D., Ph.D., Founder, Chairman and CEO at Celularity. “There is a clear need for novel therapeutic approaches to the treatment of

The Medicines Company announced that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share in an all-cash transaction, implying a fully diluted equity value of $9.7 billion. The price represents a premium of approximately 45% to The Medicines Company’s closing share price of $58.65 on November 18, 2019. The transaction was unanimously approved by the Boards of Directors of both companies. “Our company’s singular, relentless focus and the unwavering commitment of our employees have led to this opportunity to unlock the intrinsic value of inclisiran for patients and to